Top 10 Donepezil (Aricept) Generic Manufacturers in Israel
The pharmaceutical market in Israel has shown significant growth, particularly in the production and distribution of generic medications. As of 2023, the country ranks among the top ten global markets for pharmaceuticals, with a market size estimated at approximately $1 billion. The demand for generic drugs, including donepezil (commonly known by its brand name Aricept) for Alzheimer’s treatment, is on the rise, contributing to an increase in local manufacturing capabilities. In 2022, Israel exported over $1.5 billion in pharmaceuticals, highlighting its role as a key player in the global generics market.
1. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries, headquartered in Petah Tikva, is the largest generic pharmaceutical manufacturer in Israel and one of the largest worldwide. Teva produces a wide range of generic drugs, including donepezil, with an estimated market share of around 20% in the Israeli generics sector. The company reported revenues of approximately $16.5 billion in 2022.
2. Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical, based in Haifa, specializes in dermatology and other generic medications, including donepezil. With a market share of about 5% in the Israeli generics market, Taro has a production capacity of over 500 million units annually. The company reported revenues of approximately $1 billion in 2021.
3. Perrigo Company plc
Perrigo, with a significant presence in Israel, manufactures a variety of over-the-counter and prescription medications, including donepezil generics. The company’s production facility in Israel has a capacity of over 1 billion units per year. Perrigo reported net sales of $4.5 billion in 2022, with a growing focus on generics.
4. Israel Chemicals Ltd. (ICL)
Israel Chemicals Ltd. is more focused on agricultural chemicals but has diversified into pharmaceuticals, including generics. Although not a primary player in donepezil, ICL’s pharmaceutical division has been expanding, contributing to a market presence. ICL’s revenues reached approximately $6 billion in 2022.
5. Dexcel Pharma Technologies Ltd.
Dexcel Pharma, based in Or Akiva, focuses on developing and manufacturing generic drugs, including donepezil. Dexcel is known for its innovative formulations and has a production capacity exceeding 400 million units annually. The company reported revenues of approximately $200 million in 2021.
6. Intec Pharma Ltd.
Intec Pharma focuses on developing unique drug delivery systems and has entered the generics market with donepezil. While primarily a development-stage company, Intec’s innovative approach has attracted attention and partnerships. The company reported a market capitalization of around $50 million in 2023.
7. Kamada Ltd.
Kamada, an Israeli biopharmaceutical company, is involved in the production of various medicines, including generics. Although their focus is more on biologics, Kamada has started exploring the production of donepezil generics. The company reported revenues of approximately $75 million in 2022.
8. Sandoz Israel (a Novartis division)
Sandoz, a division of Novartis, is a significant player in the Israeli generics market. The company produces donepezil and has a strong market presence, with estimated revenues of around $3 billion globally. Sandoz Israel contributes to this with a solid production capacity, focusing on quality and compliance.
9. Medison Pharma Ltd.
Medison Pharma specializes in the distribution of innovative and generic medicines, including donepezil. The company has established strong relationships with healthcare providers in Israel and reported revenues of approximately $500 million in 2022, with growing sales in the generics sector.
10. Croma-Pharma GmbH
Croma-Pharma, while primarily focused on aesthetic and dermatological products, has expanded its portfolio to include generic drugs like donepezil. Their Israeli operations are expected to grow, contributing to a market share of about 2% in the generics sector. Revenues for the company reached approximately $100 million in 2022.
Insights and Trends
The generic pharmaceutical market in Israel is poised for continued growth, driven by increasing demand for cost-effective medications like donepezil. As the population ages, the prevalence of Alzheimer’s disease rises, creating a significant market opportunity for generic manufacturers. In 2023, the global generic drug market is expected to reach $450 billion, with Israel contributing significantly to these figures. With strong investments in research and development, local manufacturers are likely to enhance their production capabilities, improve quality standards, and expand their market shares in the coming years.
Related Analysis: View Previous Industry Report
